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THERAPEUTICS
Mosquito repellents for travellers
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This is one of a series of occasional articles on therapeutics for common
or serious conditions, covering new drugs and old drugs with important
new indications or concerns. The series advisers are Robin Ferner,
honorary professor of clinical pharmacology, University of Birmingham
and Birmingham City Hospital, and Albert Ferro, professor of
cardiovascular clinical pharmacology, King’s College London. To suggest
a topic, please email us at practice@bmj.com.
Case scenario
A pregnant woman visits you as her general practitioner (GP)
because she and her children will be visiting a country with
mosquito borne disease. You recommend using repellents to
protect against mosquitoes, as well as vaccinations and other
relevant disease prevention measures. She asks which repellents
would be best.
What are the active ingredients?
The key factors to consider when choosing a repellent are the
active chemical ingredients and the strength (concentration (%)
of active ingredient) because these influence the efficacy and
duration of protection.1 2 There are four active ingredients with
sufficient published scientific evidence to warrant
recommendation. Repellents are useful in areas of low risk of
mosquito borne disease to prevent nuisance biting (which may
lead to problems such as allergies) and are essential in moderate
to high risk areas (figure⇓) to prevent disease transmission (such
as malaria and dengue fever) through bites. Repellents work on
mosquitoes by directly stimulating avoidance behaviour or by
blocking the mosquito’s receptors for attractive odours, not
though toxicity.3
DEET—N,N-Diethyl-meta-toluamide has been in use since
1946 and is the “gold standard” repellent recommended by
theWorldHealth Organization Pesticide Evaluation Scheme.4
PMD—Many people prefer the idea of a “natural” repellent
to a synthetic one. p-Menthane-3,8-diol (PMD) was first
isolated as a byproduct of Eucalyptus citriodora (lemon
eucalyptus).
Icaridin—Icaridin (hydroxyethyl isobutyl piperidine
carboxylate) is also known by the trade names Bayrepel,
Picaridin, and Saltidin.
Insect Repellent 3535—IR3535 (ethyl
butylacetylaminopropionate) is a synthetic repellent that has
been less comprehensively studied.
How well do repellents work?
Although this article focuses on mosquitoes, the four
recommended active ingredients may also protect against other
arthropod vectors, such as sand flies and ticks. The
recommended active ingredients should repel up to 100% of
mosquitoes of the genera Aedes, Anopheles, and Culex for a
specified duration. Although some repellents can last up to 12
hours, the average is 4-8 hours, depending on the active agent,
application type, and the local mosquito species.2
DEET—For disease endemic countries DEET should be
present at 20-50% concentration, because several large well
conducted randomised control trials have shown that this
concentration offers complete protection by repelling 100%
of Aedes,Culex, and Anophelesmosquitoes for 6-13 hours.1 2
PMD—Repellents with 30% PMD provided complete
protection for 4-6 hours against Aedes,Culex, and Anopheles
mosquitoes in randomised controlled trials.1 2Apart from its
shorter duration of action, efficacy is similar to DEET.
Icaridin—Like DEET, in randomised controlled trials in
the field, at concentrations greater than 20%, Icaridin offered
complete protection for up to six hours against Anopheles,
Aedes, and Culex species.1
IR3535—This has shown complete protection, comparable
to DEET, at 20% concentration against several mosquito
species including Aedes and Culex for 7-10 hours in well
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The bottom line
• Always recommend a topically applied repellent with a proven active ingredient such as DEET (20-50%), PMD (30%), or Icaridin
(20-50%). IR3535 (20%) is recommended only for areas that are not malaria endemic
• Reapply repellents at least every six to eight hours if using DEET or IR3535, or every four to six hours for PMD and Icaridin, and
sooner if they wear off while swimming or sweating in warm weather
• DEET can be used on children over 8 weeks old, PMD on children over 3 years
• DEET is safe for use from the second trimester onwards and while breast feeding
replicated laboratory longevity studies and non-randomised
field trials in Thailand. However, protection time is shorter
(~3 h) against Anopheles species, so it should not be
recommended for malaria endemic regions.1
How safe are repellents?
During the 1980s and 1990s there were several reports of
encephalopathy following DEET exposure in children.1
However, risk assessments by both the US Environmental
Protection Agency (USEPA) and independent publications, as
well as a clinical trial, found no association between
encephalopathy andDEET use, and no toxological risk or severe
effects except after inappropriate use (ingestion, direct
inhalation, or eye exposure).5 PMD, Icaridin, and IR3535 have
also been registered for safe use as repellents by the USEPA6
and WHO,7 8 but have not been extensively studied in humans.
What are the precautions?
Pregnancy and breast feeding—No trials have assessed
the safety of PMD, Icaridin, or IR3535 in human pregnancy
or during breast feeding, so these drugs cannot be
recommended. A large, well conducted, double blind
randomised controlled trial (RCT) in Thailand of 897
pregnant women showed no adverse effects of topically
applied DEET in women or their infants when followed for
one year after birth, including while breast feeding.9
Participants were all in the second or third trimester,
however, and no human trials provide safety data for earlier
in pregnancy. Nonetheless, studies in rats and rabbits showed
no effects on offspring, suggesting that DEET is safe when
used as recommended.10
Children—Topical repellents are recommended for children
of all ages unless the label specifically states an age
restriction.11 Products containing DEET are considered safe
for use in children over 2 months of age.10 Products
containing PMD are not advised in children under 3 years
because of the lack of safety data for this age range.1 11 The
repellent should be applied by an adult who has thoroughly
read the directions. A third to a half of parents apply repellent
incorrectly to children—for example, by applying it to the
children’s clothing as well as their skin or by not removing
it before putting children to bed.12
Sunscreen—Limited early laboratory research suggested
that applying 33.5% DEET after sunscreen significantly
reduces the sun protection factor (SPF) of the sunscreen.13
Randomised controlled trials with Aedes and Anopheles
mosquitoes found that applying repellent concurrently with
or before sunscreen did not lessen the effect of the
repellent,14 15 but that reapplication of the sunscreen over the
repellent reduced the mean repellent protection time by one
hour.15 Thus advise travellers to apply repellent first or use
a combined repellent and sunscreen product and be aware
that repellent may wear off more quickly if reapplying only
sunscreen on top. If using a combination product, ensure
that the concentration of repellent is sufficient.
How are they used?
Recommend topical repellents, such as lotions and sprays,
because they are the most studied and have the greatest efficacy.1
The repellent should be effective against the vector species
present at the destination. Thus, although all four repellents are
effective, do not recommend IR3535 for malaria endemic
regions, given its shorter duration of action against Anopheles
spp. Apply evenly to all exposed skin except the face (to avoid
accidental eye exposure or ingestion) during times of risk (at
dawn, dusk, and evening for most regions, but also during the
day, particularly in South East Asia, South America, and in
forested areas). Although every product is different, as a general
rule, re-apply DEET and IR3535 every six to eight hours, and
PMD and Icaridin every four to six hours.1 2 The tips for
travellers box provides more detail on appropriate use.
How do they compare with alternatives?
An RCT compared common commercial products containing
essential oils, vitamin B1, or the insecticide metofluthrin, in
different delivery systems, including wristbands, stickers,
patches, sonic devices, and diffusers.16 It found that only the
personal diffusers containing metofluthrin or a mix of essential
oils had any repellent effect, reducing localised biting by
87-95%. There is no evidence that any of these devices provide
adequate protection for areas with mosquito borne disease.
Other active ingredients include essential oils such as citronella,
neem, thyme, geraniol, peppermint, patchouli, and clove.
Because these compounds are volatile, efficacy is variable. They
may provide 20-100% protection for about two hours, but a
recent systematic review of laboratory and field trials found no
evidence that they can protect against disease transmission.17
There is anecdotal evidence that a change in diet and vitamin
supplements can protect against mosquito bites. Although this
has not been looked at extensively, an RCT of the effect of
vitamin B12 on human odour showed that it has no effect on
mosquito biting rates.18 A double blinded RCT that tested the
effect of garlic supplements as mosquito repellents found no
protective effect.19 Intake of supplements like vitamin B or garlic
should not be recommended for protection against mosquitoes.
Outcome
You recommend a topical repellent with DEET (20-50%)
because it is effective and safe for pregnant women and children
and provide advice on how to apply it (see tips for travellers
box).
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Tips for travellers
Use a repellent containing 20-50% DEET or Icaridin, or 30% PMD. Use IR3535 (20%) only if travelling to a country without malaria.
Higher concentrations of DEET will repel mosquitoes for longer than lower concentrations. However, products with greater than 50%
DEET are not recommended
Essential oils such as citronella, repellent wristbands, garlic supplements, and vitamin B12 do not provide adequate protection against
biting and disease transmission
Apply repellent evenly to all exposed skin except the face, particularly when there are lots of mosquitoes, such as in the early morning
and the evening, but also during the day if mosquitoes are present
DEET and IR3535 should be reapplied every six to eight hours, and PMD and Icaridin every four to six hours, unless stated otherwise
on the label. If swimming or sweating in warm weather, they may wear off sooner and will need to be reapplied
Apply repellent and sunscreen simultaneously or repellent first; if using a combination product, check that it contains the right concentration
of repellent (20-50% DEET)
You can safely use DEET when pregnant (from the second trimester onwards), when breast feeding, and on children over 2 months
old. Thoroughly cover the child’s exposed skin (except the face), not clothing, and ensure that you wash it off before bed
Additional resources: www2.epa.gov/insect-repellents; wwwnc.cdc.gov/travel/page/avoid-bug-bites
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Figure
Areas of low, moderate, and high risk of mosquito borne disease worldwide
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2015;350:h99 doi: 10.1136/bmj.h99 (Published 19 February 2015) Page 4 of 4
PRACTICE
